Acta Neuropathol

1. ONO D, Kondrakunta S, Mak E, Przybelski SA, et al
   Neuropathologic basis of quantitative susceptibility mapping in the substantia nigra: contributions of tau, pigmented neurons, and iron.
   Acta Neuropathol. 2026;151:17.
   

   >> Share

   
   

   
   Alzheimer Dis Assoc Disord

2. EJIOFOR T, Oluwafunmilayo J O, Kala A, Ephraim AD, et al
   Structural Brain Correlates With Appetite and Eating Disturbances Across the Alzheimer Disease Spectrum.
   Alzheimer Dis Assoc Disord. 2026 Feb 17. doi: 10.1097/WAD.0000000000000719.
   

   >> Share

   
   

   
   Alzheimers Dement

3. LISGARAS CP, Scharfman HE
   The cholinergic system exerts opposing effects on memory at different stages of disease progression in Alzheimer's and Down syndrome model systems.
   Alzheimers Dement. 2026;22:e71154.
   

   >> Share

   
   
4. KESHAVAN A, Wiltshire K, Wee R, Belio IG, et al
   The Alzheimer's Disease Diagnosis and Plasma Phospho-Tau217 (ADAPT) study stage 1: Validating clinical cut-points against CSF and amyloid PET.
   Alzheimers Dement. 2026;22:e71147.
   

   >> Share

   
   
5. LI A, Klinger HM, Seto M, Birkenbihl C, et al
   Elevated temporal tau PET predicts faster cognitive decline in women than men: A meta-analysis.
   Alzheimers Dement. 2026;22:e71031.
   

   >> Share

   
   
6. KIM HK, Lee JH, Chun JH, Kim YJ, et al
   Plasma p-tau217 predicts PET-based pathological staging for precision Alzheimer disease assessment.
   Alzheimers Dement. 2026;22:e71199.
   

   >> Share

   
   
7. BENEJAM B, McCarron M, Carmona-Iragui M, Dunne P, et al
   Factors impacting survival in individuals with Down syndrome-associated Alzheimer's disease.
   Alzheimers Dement. 2026;22:e71156.
   

   >> Share

   
   
8. CAO H, Zheng Z, Zhou X, Kikuchi M, et al
   Ethnic-specific effects of the LILRB2-LILRB5 locus and newly identified risk loci for Alzheimer's disease in the East Asian population.
   Alzheimers Dement. 2026;22:e71219.
   

   >> Share

   
   

   
   BMC Neurol

9. MOHAMMADI H, Maghsoudpour A, Noroozian M, Mohammadian F, et al
   Turning versus straight walking under dual-task conditions: a preliminary study for identifying mild cognitive impairment and Alzheimer's disease.
   BMC Neurol. 2026 Feb 19. doi: 10.1186/s12883-026-04723.
   

   >> Share

   
   

   
   Brain

10. LAGARTOS-DONATE MJ, Escobar-Doncel B, Zhang SQ, Pan JP, et al
    Loss of REST associated with Alzheimer's disease pathology is ameliorated by NAD.
    Brain. 2026 Feb 19:awaf261. doi: 10.1093.
    

    >> Share

    
    

    
    Curr Opin Neurol

11. MATHOUX G, Harput E, Peretti DE, Boccalini C, et al
    Clinical amyloid and tau positron emission tomography imaging in Alzheimer's disease: image interpretation in the era of anti-amyloid therapies.
    Curr Opin Neurol. 2026 Feb 20. doi: 10.1097/WCO.0000000000001471.
    

    >> Share

    
    
12. RUSSELL JK, Schlachetzki Z, Rafii MS
    Decoding Alzheimer's disease through down syndrome: insights from a genetically defined population.
    Curr Opin Neurol. 2026 Feb 19. doi: 10.1097/WCO.0000000000001461.
    

    >> Share

    
    

    
    Exp Neurol

13. LI J, Sun W, Guo S, Bai J, et al
    The role of IGF1 signaling in remote ischemic conditioning-mediated amelioration of Alzheimer's disease pathology and cerebral insulin resistance.
    Exp Neurol. 2026 Feb 18:115685. doi: 10.1016/j.expneurol.2026.115685.
    

    >> Share

    
    

    
    J Alzheimers Dis

14. BAFAIL DA
    The cognitive neutrality of common antidiabetic medications in older adults: A propensity score-matched cohort analysis from the National Alzheimer's Coordinating Center database.
    J Alzheimers Dis. 2026 Feb 17:13872877251410210. doi: 10.1177/13872877251410210.
    

    >> Share

    
    
15. LI X, Zhang Y, Shi X, Li D, et al
    A novel presenilin 1 nucleotide mutation (M139I) and its pathological function in a Chinese family with early-onset Alzheimer's disease.
    J Alzheimers Dis. 2026 Feb 18:13872877261418314. doi: 10.1177/13872877261418314.
    

    >> Share

    
    

    
    J Am Geriatr Soc

16. ARAVENA JM, Castro H, Poblete R, Aravena MI, et al
    A Health Communication Strategy to Promote Dementia Risk Reduction: The CULTIVAMENTE Pragmatic Cluster-Randomized Trial.
    J Am Geriatr Soc. 2026;74:418-429.
    

    >> Share

    
    

    
    J Neurochem

17. RUANKHAM W, Prachayasittikul V, Pingaew R, Jeungprasopsuk W, et al
    Unraveling Network Pharmacology-Based Therapeutics of Anthranilate Sulfonamides via Sirtuins/FOXO3a Cascade in Alzheimer's Disease.
    J Neurochem. 2026;170:e70377.
    

    >> Share

    
    

    
    J Neurol

18. BAMFORD AR, Logan C, Do QT, Nguyen K, et al
    Salivary total tau: a clinically practical measure of tau neuropathology in Alzheimer's disease.
    J Neurol. 2026;273:149.
    

    >> Share

    
    

    
    J Neurol Neurosurg Psychiatry

19. MICHALON R, Planche V, Lemoine M, Keuck L, et al
    Defining Alzheimer's disease: stipulations and the ethics of diagnostic change.
    J Neurol Neurosurg Psychiatry. 2026 Feb 17:jnnp-2025-337832.
    

    >> Share

    
    

    
    J Neurosci

20. BLANKENSHIP HE, Higgs MH, Harold KM, Humphries KM, et al
    Alzheimer's pathology enhances excitatory synaptic input and integration in VTA dopamine neurons.
    J Neurosci. 2026 Feb 17:e2085252026. doi: 10.1523/JNEUROSCI.2085-25.2026.
    

    >> Share

    
    

    
    Nat Med

21. O'LEARY K
    A tumor-secreted protein alleviates Alzheimer's disease pathology.
    Nat Med. 2026 Feb 20. doi: 10.1038/d41591-026-00010.
    

    >> Share

    
    
22. PETERSEN KK, Mila-Aloma M, Li Y, Du L, et al
    Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.
    Nat Med. 2026 Feb 19. doi: 10.1038/s41591-026-04206.
    

    >> Share

    
    

    
    Nat Neurosci

23. DE SCHEPPER S, Ge JZ, Sierksma A, Crowley G, et al
    Author Correction: Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer's disease.
    Nat Neurosci. 2026 Feb 17. doi: 10.1038/s41593-025-02197.
    

    >> Share

    
    

    
    Nature

24. LEDFORD H
    Blood test holds promise for predicting when Alzheimer's symptoms will start.
    Nature. 2026 Feb 19. doi: 10.1038/d41586-026-00531.
    

    >> Share

    
    

    
    Neurobiol Aging

25. BUDAK M, Fausto BA, Paruzel V, White P, et al
    ABCA7 rs115550680 risk allele carriers have lower medial temporal lobe dynamic network flexibility than APOE-epsilon4 allele carriers among older African Americans.
    Neurobiol Aging. 2026;161:64-72.
    

    >> Share

    
    
26. MOTAMED Z, Novack G, Heutschi D, Gaiser C, et al
    Human in vitro and rodent in vivo models highlight progressive mitochondrial dysfunction as a starting point of cerebral amyloidosis.
    Neurobiol Aging. 2026;161:47-63.
    

    >> Share

    
    

    
    Neurochem Res

27. NISAR A, Akhter N, Chauhdary Z, Anjum F, et al
    Investigating the Neuroprotective Effects of Saw Palmetto Fruit Extract Against D-Galactose and Aluminum Chloride Induced Alzheimer's Disease: In Vivo Study.
    Neurochem Res. 2026;51:76.
    

    >> Share

    
    
28. CAKIR A, Sehzade S, Koc C, Cilingir S, et al
    The Impact of REM Sleep Deprivation on ER Stress and Alzheimer-Like Pathology: Therapeutic Potential of Melatonin.
    Neurochem Res. 2026;51:79.
    

    >> Share

    
    

    
    Neurology

29. BIEGER A, Brum WS, Borelli WV, Ferrari-Souza JP, et al
    Reader Response: The Great Debate in Diagnosing Alzheimer Disease: More Than Just a beta Test.
    Neurology. 2026;106:e210159.
    

    >> Share

    
    
30. GANESH A, Galetta SL
    Editors' Note: Diagnostic and Prognostic Implications of Biomarker-Based Criteria for Alzheimer Disease.
    Neurology. 2026;106:e214259.
    

    >> Share

    
    
31. VILLAIN N, Hanseeuw BJ, Planche V, Paretsky MS, et al
    Author Response: The Great Debate in Diagnosing Alzheimer Disease: More Than Just a beta Test.
    Neurology. 2026;106:e210240.
    

    >> Share

    
    
32. VILLAIN N
    Reader Response: Alzheimer Disease Is a Specific Disorder Defined by Neuropathology Detectable During Life.
    Neurology. 2026;106:e210188.
    

    >> Share

    
    

    
    Neuroscience

33. HE L, Xiaopeng Z, Juan D, Yan L, et al
    Anti-ASC antibodies alleviate Alzheimer's disease-type pathology in APP/PS1 mice.
    Neuroscience. 2026;599:152-161.
    

    >> Share

    
    
34. MINAURO-SANMIGUEL F, Vargas-Perez H
    Mitochondria-associated membranes and hallucinogenic therapy in Alzheimer's disease.
    Neuroscience. 2026 Feb 16:S0306-4522(26)00125.
    

    >> Share

    
    

    
    PLoS Med

35. DENG Y, Liu Y, Hao H, Xu K, et al
    The role of comorbidities in the associations between air pollution and Alzheimer's disease: A national cohort study in the American Medicare population.
    PLoS Med. 2026;23:e1004912.
    

    >> Share

    
    

    
    PLoS One

36. HERNANDEZ NM, Silva-Perez M, Chin J
    Noradrenergic innervation across brain regions is altered by aging and by disease progression in a mouse model of Alzheimer's disease neuropathology.
    PLoS One. 2026;21:e0340611.
    

    >> Share

    
    
37. LI R, Jiang S, Pi Z, Chen G, et al
    Early diagnosis of Alzheimer's Disease: Graph theoretical analysis of cerebellar network features based on 18F-AV45 PET.
    PLoS One. 2026;21:e0342738.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

38. CHEN J, Xu M, Liu Y, Hadi F, et al
    RNA-binding activity of PHGDH drives amyloid-beta production in a human brain organoid model of sporadic Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2026;123:e2532234123.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share